TrialJournal of bone and mineral metabolism2019

Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.

Toshitsugu Sugimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.